PAVmed Inc. (NASDAQ:PAVM) Short Interest Up 161.8% in January

PAVmed Inc. (NASDAQ:PAVM) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 129,582 shares, an increase of 161.8% from the January 15th total of 49,495 shares. Currently, 14.5% of the company’s shares are short sold. Based on an average daily volume of 5,566,555 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 5,566,555 shares, the days-to-cover ratio is presently 0.0 days. Currently, 14.5% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several research analysts recently commented on PAVM shares. Zacks Research lowered shares of PAVmed from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research report on Thursday, January 22nd. Finally, Ascendiant Capital Markets reduced their target price on shares of PAVmed from $600.00 to $510.00 and set a “buy” rating on the stock in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $510.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PAVmed stock. Geode Capital Management LLC raised its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 74.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 168,832 shares of the company’s stock after buying an additional 72,258 shares during the quarter. Geode Capital Management LLC owned 17.23% of PAVmed worth $40,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.93% of the company’s stock.

PAVmed Stock Down 5.2%

NASDAQ PAVM traded down $0.54 during trading hours on Thursday, hitting $9.92. The company had a trading volume of 28,842 shares, compared to its average volume of 2,115,661. The firm has a market cap of $9.72 million, a P/E ratio of -0.58 and a beta of 1.12. PAVmed has a fifty-two week low of $6.00 and a fifty-two week high of $28.44. The business has a fifty day simple moving average of $8.95 and a 200-day simple moving average of $11.63.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.